Phosphoproteomic analysis of cell-based resistance to BRAF inhibitor therapy in melanoma

Robert Parker, Laura J. Vella, Dylan Xavier, Ardeshir Amirkhani, Jimmy Parker, Jonathan Cebon, Mark P. Molloy*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    21 Citations (Scopus)
    56 Downloads (Pure)

    Abstract

    The treatment of melanoma by targeted inhibition of the mutated kinase BRAF with small molecules only temporarily suppresses metastatic disease. In the face of chemical inhibition tumor plasticity, both innate and adaptive, promotes survival through the biochemical and genetic reconfiguration of cellular pathways that can engage proliferative and migratory systems. To investigate this process, high-resolution mass spectrometry was used to characterize the phosphoproteome of this transition in vitro. A simple and accurate, label-free quantitative method was used to localize and quantitate thousands of phosphorylation events. We also correlated changes in the phosphoproteome with the proteome to more accurately determine changes in the activity of regulatory kinases determined by kinase landscape profiling. The abundance of phosphopeptides with sites that function in cytoskeletal regulation, GTP/GDP exchange, protein kinase C, IGF signaling, and melanosome maturation were highly divergent after transition to a drug resistant phenotype.

    Original languageEnglish
    Article number95
    Pages (from-to)1-13
    Number of pages13
    JournalFrontiers in Oncology
    Volume5
    DOIs
    Publication statusPublished - 2015

    Bibliographical note

    Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

    Keywords

    • phosphoproteomics
    • BRAF
    • drug resistance
    • vemurafenib
    • kinases
    • label-free quantitation
    • mass spectrometry

    Fingerprint

    Dive into the research topics of 'Phosphoproteomic analysis of cell-based resistance to BRAF inhibitor therapy in melanoma'. Together they form a unique fingerprint.

    Cite this